Expanded access to triheptanoin
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This expanded access program provides triheptanoin to people who cannot take part in another clinical trial for this medication. The goal is to offer treatment when other options are not available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are not able to join another clinical trial for triheptanoin (UX007).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oil called triheptanoin for children with a rare genetic condition (PDCD) that affects how their bodies use energy. The study aims to see if triheptanoin can help improve their health.
This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.
This trial tests an investigational medication, MAR001, to see if it can lower high levels of fats in the blood (triglycerides and remnant cholesterol) linked to heart disease. If you have these conditions, this treatment might help reduce your risk.
This trial tests a new medication for people with moderate-to-severe eczema. It aims to see if the treatment is safe and effective for reducing symptoms.
This trial tests a new injectable drug called DR10624 for people with very high triglyceride levels. It aims to lower triglycerides and reduce the risk of pancreatitis (inflammation of the pancreas).
This trial is for people with a specific inherited form of amyloidosis caused by a change in the TTR gene. It offers a comprehensive care program to help manage this rare condition.
Hear when a new Long Chain Fatty Acid Oxidation Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.